Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BJU Int
    October 2025
  1. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
    Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
    BJU Int. 2025;136:728-737.
    >> Share

  2. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    External validation of the Uromonitor(R)-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.
    BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010.
    >> Share

    September 2025
  3. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
    Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
    >> Share

  4. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
    Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
    BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
    >> Share

  5. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
    Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
    BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
    >> Share

    August 2025
  6. ZAURITO P, Scilipoti P, Longoni M, Viti A, et al
    The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
    >> Share

  7. DEY L, Rautiola J, Akre O, Egevad L, et al
    Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
    >> Share

  8. DE ANGELIS M, Scilipoti P, Santangelo A, Longoni M, et al
    The impact of histopathological evaluation at transurethral resection of bladder tumour on survival in radical cystectomy candidates.
    BJU Int. 2025;136:336-343.
    >> Share

  9. BEN-DAVID R, Pellegrino F, Mehrazin R, Thomas J, et al
    Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy.
    BJU Int. 2025;136:321-328.
    >> Share

    July 2025
  10. LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al
    Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
    >> Share

  11. HOF J, Vermeulen S, Richters A
    Biased associations between number of BCG instillations and outcome in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16866.
    >> Share

  12. VON DEIMLING M, Furrer M, Bianchi A, Pichler R, et al
    Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer.
    BJU Int. 2025 Jul 9. doi: 10.1111/bju.16851.
    >> Share

  13. TEMPO J, Felemban S, Qin KR, Perera M, et al
    Radical cystectomy mortality in older patients: a systematic review and meta-analysis.
    BJU Int. 2025;136:19-31.
    >> Share

    June 2025
  14. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    >> Share

  15. FERRO M, Catellani M, Bianchi R, Fallara G, et al
    Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828.
    >> Share

  16. ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al
    Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel.
    BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827.
    >> Share

  17. HANEY CM, Studier-Fischer A, Geissler ME, Ohlmeier J, et al
    Indocyanine-guided ureter resection for radical cystectomy - a systematic review and meta-analysis.
    BJU Int. 2025;135:908-917.
    >> Share

  18. AMPARORE D, De Cillis S, Colombo M, Garzena V, et al
    TYTOCARE home telemonitoring device after radical cystectomy to optimise postoperative outcomes.
    BJU Int. 2025;135:960-968.
    >> Share

    May 2025
  19. KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al
    Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.
    BJU Int. 2025 May 26. doi: 10.1111/bju.16793.
    >> Share

  20. VAN HATTUM JW, Remmelink MJ, Nuijens ST, de Ruiter BM, et al
    A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer.
    BJU Int. 2025 May 22. doi: 10.1111/bju.16767.
    >> Share

  21. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
    Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.
    BJU Int. 2025 May 21. doi: 10.1111/bju.16780.
    >> Share

  22. BOSVELD J, Nguyen TQ, Boormans JL, Witjes JA, et al
    The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.
    BJU Int. 2025;135:766-774.
    >> Share

    April 2025
  23. NUIJENS ST, van Hoogstraten LMC, Terpstra NB, Beeren I, et al
    The impact of treatment for muscle-invasive bladder cancer on health-related quality of life.
    BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736.
    >> Share

  24. BRYAN RT, Patel P, Kennish SJ, Catto JWF, et al
    Improving the pathway to correct treatment for patients with muscle-invasive bladder cancer: exploring the myths around the BladderPath trial.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728.
    >> Share

    March 2025
  25. COLLETT G, Bashford T, Whitehead NJ, Kazimierska E, et al
    Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army.
    BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
    >> Share

  26. TREVISANI F, Floris M, Longoni M, Rosiello G, et al
    Acute kidney disease after radical cystectomy for bladder cancer: a new onco-nephrological view.
    BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
    >> Share

  27. ROLDAN FL, Ingelmo-Torres M, Mercader C, Figueras M, et al
    Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16697.
    >> Share

  28. CHOWDHURY D, Apolo AB, Jiang DM, Skinner EC, et al
    Understanding patient perspectives in the management of their muscle-invasive bladder cancer.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16695.
    >> Share

  29. RAUTIOLA J, Bjorklund J, Ben-David R, Skokic V, et al
    Pelvic organ-sparing robot-assisted radical cystectomy in women with bladder cancer.
    BJU Int. 2025 Mar 4. doi: 10.1111/bju.16691.
    >> Share


  30. Advances in the management of high-risk localised muscle invasive bladder cancer.
    BJU Int. 2025;135:364-365.
    >> Share

  31. STRUCK JP, Moharam N, Leitenberger A, Weber J, et al
    An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.
    BJU Int. 2025;135:446-455.
    >> Share

  32. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes.
    BJU Int. 2025;135:473-480.
    >> Share

    February 2025
  33. TILLU N, Ben-David R, Skokic V, Rich JM, et al
    Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16686.
    >> Share

  34. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Feb 18. doi: 10.1111/bju.16675.
    >> Share

    January 2025
  35. BEEREN I, Meijer H, van der Heijden AG, Aben KKH, et al
    Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 25. doi: 10.1111/bju.16665.
    >> Share

  36. KLUGER N, van der van der Bent SAS
    Tattoos as a risk factor for bladder cancer: a call for cohort studies.
    BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
    >> Share

  37. OLAH C, Sichward L, Hadaschik B, Darr C, et al
    Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
    BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
    >> Share

  38. SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al
    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
    BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645.
    >> Share

  39. PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
    National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
    BJU Int. 2025;135:140-147.
    >> Share

  40. JOHN JB, Collins M, Eames S, O'Flynn K, et al
    The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
    BJU Int. 2025;135:78-87.
    >> Share

    December 2024
  41. LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
    Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
    BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
    >> Share

  42. HAILE ES, Lone Z, Shin D, Nowacki AS, et al
    Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
    >> Share

  43. PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
    International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
    BJU Int. 2024;134:932-938.
    >> Share

  44. GUO AA, Zeng K, Bushati Y, Kim P, et al
    Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
    BJU Int. 2024;134 Suppl 2:22-29.
    >> Share

  45. AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
    Long-term quality of life in patients with bladder cancer following radical cystectomy.
    BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
    >> Share

    November 2024
  46. LONE Z, Shin D, Nowacki A, Campbell RA, et al
    Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
    BJU Int. 2024;134:841-847.
    >> Share

  47. DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
    A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
    BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
    >> Share

    October 2024
  48. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    >> Share

  49. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
    Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.
    BJU Int. 2024 Oct 21. doi: 10.1111/bju.16565.
    >> Share

  50. DEL GIUDICE F, Vestri A, Fegatelli DA, Husch T, et al
    VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
    BJU Int. 2024 Oct 13. doi: 10.1111/bju.16531.
    >> Share

  51. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
    Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
    BJU Int. 2024;134:541-550.
    >> Share

  52. RIEGER C, Schluchtermann J, Storz E, Kastner L, et al
    Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
    BJU Int. 2024;134:582-588.
    >> Share

    September 2024
  53. CONROY S, Jubber I, Noon AP, Rosario DJ, et al
    Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
    BJU Int. 2024 Sep 26. doi: 10.1111/bju.16516.
    >> Share

  54. LIU K, Nicoletti R, Zhao H, Chen X, et al
    The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
    BJU Int. 2024 Sep 10. doi: 10.1111/bju.16493.
    >> Share

  55. VACCARO C, Dewulf K, Richter K, Branger N, et al
    Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique.
    BJU Int. 2024;134:501-503.
    >> Share

  56. ZENNAMI K, Kusaka M, Tomozawa S, Toda F, et al
    Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion.
    BJU Int. 2024;134:426-433.
    >> Share

  57. D'ANDREA D, Soria F, Moschini M, Laukhtina E, et al
    Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy.
    BJU Int. 2024;134:459-464.
    >> Share

  58. AFFERI L, Spahn M, Hayoz S, Strebel RT, et al
    Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
    BJU Int. 2024;134:388-397.
    >> Share

    August 2024
  59. SU ZT, Florissi IS, Mahon KM, Li T, et al
    Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16521.
    >> Share

  60. TAYLOR JI, Kamat AM, O'Donnell MA, Annapureddy D, et al
    Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
    BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509.
    >> Share

  61. HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
    Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
    BJU Int. 2024;134:229-238.
    >> Share

  62. MATSUDA A, Taoka R, Miki J, Saito R, et al
    Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
    BJU Int. 2024;134:207-218.
    >> Share

    July 2024
  63. CHAKRA MA, Lassila R, El Beayni N, Mott SL, et al
    Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
    BJU Int. 2024 Jul 31. doi: 10.1111/bju.16486.
    >> Share

  64. REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
    Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
    >> Share

  65. ANTONELLI L, Wendel-Garcia PD, Deforth M, Afferi L, et al
    Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
    BJU Int. 2024 Jul 3. doi: 10.1111/bju.16444.
    >> Share


  66. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int. 2024;134:4-5.
    >> Share

  67. PELLEGRINO F, Scilipoti P, Rosiello G, Longoni M, et al
    Long-term functional outcomes after robot-assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
    BJU Int. 2024;134:48-50.
    >> Share

  68. TUDERTI G, Mastroianni R, Anceschi U, Bove AM, et al
    Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series.
    BJU Int. 2024;134:103-109.
    >> Share

  69. MYERS AA, Tan WS, de Groot J, Westney OL, et al
    'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder.
    BJU Int. 2024;134:45-47.
    >> Share

  70. TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
    Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    BJU Int. 2024;134:43-44.
    >> Share

  71. AN X, Xue C, Chen M, Ni M, et al
    Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
    BJU Int. 2024;134:63-71.
    >> Share

    June 2024
  72. WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
    Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
    BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
    >> Share

  73. FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
    Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
    >> Share

  74. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
    How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2024;133:673-677.
    >> Share

    May 2024
  75. FINOCCHIARO A, Paciotti M, Contieri R, Fasulo V, et al
    Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
    BJU Int. 2024 May 22. doi: 10.1111/bju.16406.
    >> Share

  76. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
    Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
    BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
    >> Share

    April 2024
  77. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
    Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
    BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
    >> Share

  78. SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
    Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
    BJU Int. 2024 Apr 24. doi: 10.1111/bju.16364.
    >> Share

  79. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
    Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
    >> Share

  80. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
    Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
    >> Share

  81. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
    Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
    >> Share

  82. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
    Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
    BJU Int. 2024;133:474-479.
    >> Share

  83. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
    Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
    BJU Int. 2024;133 Suppl 4:53-63.
    >> Share

  84. BOTROS A, Rival PM, Page F, Davis ID, et al
    Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
    BJU Int. 2024;133 Suppl 4:7-10.
    >> Share

    March 2024
  85. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
    Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
    BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
    >> Share

  86. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
    The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
    >> Share

  87. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
    The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
    >> Share

    February 2024
  88. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
    A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
    >> Share

  89. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
    Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
    >> Share

  90. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    >> Share


  91. Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int. 2024;133:122-123.
    >> Share

  92. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
    Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
    BJU Int. 2024;133:154-157.
    >> Share

    January 2024
  93. LU SM, Zhang Y, Dong XT, Wang JL, et al
    Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
    BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
    >> Share

  94. YIM A, Alberto M, Sharma V, Green A, et al
    Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
    >> Share

    December 2023
  95. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    >> Share

  96. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    >> Share

  97. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    >> Share

    November 2023
  98. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    >> Share

  99. CHEDGY ECP, Tang R, Struss WJ, Lowe G, et al
    A randomized controlled trial investigating rectus sheath catheters following radical cystectomy.
    BJU Int. 2023;132:554-559.
    >> Share

    October 2023
  100. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    >> Share

  101. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    >> Share

  102. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    >> Share

  103. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    >> Share

    September 2023
  104. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    >> Share

    August 2023
  105. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    >> Share

    July 2023
  106. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    >> Share

  107. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    >> Share


  108. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    >> Share

  109. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    >> Share

    June 2023
  110. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    >> Share

  111. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    >> Share

  112. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    >> Share

  113. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    >> Share

    May 2023
  114. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    >> Share

  115. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    >> Share

  116. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    >> Share

    April 2023
  117. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    >> Share

  118. FREGO N, Contieri R, Diana P, Mancon S, et al
    Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
    BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
    >> Share

  119. ROSE KM, Narang G, Rosen G, Labatte C, et al
    Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
    BJU Int. 2023;131:471-476.
    >> Share

  120. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
    Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
    BJU Int. 2023;131:477-485.
    >> Share

    March 2023
  121. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
    Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
    BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
    >> Share

  122. BESIROGLU H
    Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
    BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
    >> Share

  123. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016